How to build a biotech uni­corn: Get the star team in place, at­tract deep-pock­et VCs, paint a big pic­ture and raise up to $1B

When Steve Harr sketched out the bare­bones es­sen­tials of his strate­gic plan for the new cell ther­a­py com­pa­ny Sana Biotech­nol­o­gy a few days ago, he was care­ful to steer clear of de­tail­ing his ex­act plans for his first big raise for the biotech. But some num­bers have been start­ing to ap­pear — and not sur­pris­ing­ly they paint a pic­ture of a young uni­corn still at foal stage.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER